This site is for New Zealand healthcare professionals. If you are a patient, please click here.

Please enter your email address to view the content of this website.

Not a member? Register
You are here: Home / Our Medicines

What are our core medicines?

They target HER2, CD20, VEGF, BRAF, IL6, the hedgehog pathway and lung fibrosis.

Explore below everything you need to know: booklets and forms, efficacy and safety information and useful resources.
For a full list of our products visit


Actemra is an anti-IL6 receptor antibody for rheumatoid arthritis, systemic juvenile idiopathic arthritis, and polyarticular juvenile idiopathic arthritis.


Avastin is a VEGF inhibitor used to treat a wide range of cancers.


Erivedge is a hedgehog pathway inhibitor for adults with advanced basal cell carcinoma.


Esbriet is an oral medicine for patients with idiopathic pulmonary fibrosis (IPF)


GAZYVA is an anti-CD20 therapy for first line chronic lymphocytic leukaemia.


Herceptin targets HER2 in early and metastatic breast cancer, as well as gastric cancer.


Kadcyla is an antibody-drug conjugate for HER2-positive metastatic breast cancer.


MabThera is an anti-CD20 therapy for rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.


MabThera targets the CD20 antigen to treat non-Hodgkin lymphoma and chronic lymphocytic leukaemia.


OCREVUS is a monoclonal antibody that selectively targets CD20-expressing B-cells in Multiple Sclerosis


Perjeta is a HER2 dimerisation inhibitor for neoadjuvant (eBC) and advanced breast cancer.


Zelboraf is a BRAF kinase inhibitor for metastatic melanoma.